



FreeStyle
Libre



DHA Has Expanded CGM Coverage for All Insulin Users¹


The patient has a diagnosis of T1 diabetes or T2 diabetes mellitus, and one of the following situations applies²:

Patient is using basal and prandial insulin injections,
OR

Patient is using a continuous subcutaneous
insulin infusion (ie, insulin pump),
OR

OR

Patient has Type 2 diabetes mellitus and is
receiving insulin therapy and has a history
of severe hypoglycemia episodes requiring
medical intervention.



The patient has a diagnosis
of diabetes and is currently
being **treated with insulin**¹.

Automated PA: The patient
has filled a prescription for
insulin during the **previous
180 days***¹.

DHA = Defense Health Agency, PA=Prior Authorization


* If automated criteria are not met, coverage is manually approved for FreeStyle Libre 2 systems and FreeStyle Libre 3 systems if all criteria are met.

1. Department of Defense Pharmacy and Therapeutics Committee Recommendations from the February 2024 meeting, <https://health.mil/Reference-Center/Meeting-References/2024/03/27/UF-BAP-Background-Document-April-3-2024-time-zone-edited>. Accessed May 9, 2024. **2.** Department of Defense Pharmacy and Therapeutics Committee Recommendations from the November 2022 Meeting Information for the Uniform Formulary Beneficiary Advisory Panel, <https://www.health.mil/Reference-Center/Meeting-References/2022/12/16/BAP-Background-Document-for-the-Nov-2022-PT-Meeting>. Accessed May 17, 2024.


See last page for **Important Safety Information**.



Only about 1 in 5 insulin users in the US are at their A1c goal of <7%^{1,2}



Reductions in A1c were observed in people with diabetes across treatment regimens after using FreeStyle Libre systems^{‡3-4,§||5-6}



Help your insulin users achieve better outcomes with FreeStyle Libre CGM systems



FreeStyle Libre



T1D: type 1 diabetes; T2D: type 2 diabetes; MDI: multiple daily injections

* 2016-2018 data. † 2012-2015 data. ‡ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products.

§ Data from this study was collected with the US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre system 14 day with real-time glucose alarms. Therefore the study data is applicable to both products. || Data from this study was collected with the US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products. †† Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products. # Baseline A1c between 8% and 12%.

1. Foster, N. *Diabetes Tech Ther* (2019). <https://doi.org/10.1089/dia.2018.0384>. 2. Brixner, D. *Clinical Ther* (2019). <https://doi.org/10.1016/j.clinthera.2018.12.014>. 3. Tyndall, V. *Diabetologia* (2019): <https://doi.org/10.1007/s00125-019-4894-1>. 4. Kroger, J. *Diabetes Ther* (2020): <https://doi.org/10.1007/s13300-019-00741-9>. 5. Carlson, A. *BMJ Open Diabetes Res Care* (2022). <https://doi.org/10.1136/bmjdr-2021-002590>. 6. Wright, E. *Diabetes Spectr* (2021). <https://doi.org/10.2337/ds20-0069>.

Important Safety Information

FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or <https://www.FreeStyle.abbott/us-en/safety-information.html> for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.